Rezidüel Uykululuk Nedenleri ve Tedavisi
Özet
Rezidüel uykululuk, obstrüktif uyku apne sendromu (OUAS) olan hastalarda, apne-hipopne indeksinin (AHİ) pozitif hava yolu basıncı (PAP) tedavisiyle hedeflenen düzeye düşmesine rağmen gündüz aşırı uykululuk halinin (GAUH) sebat etmesi durumudur. PAP tedavisi alan OUAS hastalarının yaklaşık %12-14'ünde GAUH görülmekte, diğer faktörler dışlandığında net rezidüel uykululuk oranı %6 civarında seyretmektedir. Bu durumun nedenleri arasında yetersiz uyku süresi, yanlış OUAS tanısı veya hatalı CPAP titrasyonu, yetersiz tedavi kompliyansı, kötü uyku hijyeni, depresyon, narkolepsi, idiyopatik hipersomni ile kilo alımı gibi faktörler yer alır. Tedavide, kompliyansı artırmak için en az haftada 5 gece ve gecelik 4 saat kullanım sağlanmalı; nemlendirici üniteleri ve rampa fonksiyonları gibi cihaz uyumunu kolaylaştırıcı çözümler değerlendirilmelidir. CPAP tedavisine tam uyum gösteren ancak uykululuk hali devam eden dirençli vakalarda, gün boyu uyanıklık sağlayan ve hücre dışı dopamin düzeyini artıran modafinil ile armodafinil gibi stimülan ilaçların kullanımı etkin ve güvenilir bir tedavi yöntemi olarak kabul edilmektedir.
Residual sleepiness is defined as the persistence of excessive daytime sleepiness (EDS) in patients with obstructive sleep apnea syndrome (OSAS) despite effective positive airway pressure (PAP) therapy that successfully normalizes the apnea-hypopnea index (AHI). While EDS is observed in approximately 12-14% of OSAS patients receiving PAP therapy, the actual rate of residual sleepiness drops to nearly 6% once all other potential causes are excluded. The primary etiologies underlying this condition include insufficient sleep duration, inaccurate OSAS diagnosis, improper CPAP titration, inadequate treatment compliance, poor sleep hygiene, depression, narcolepsy, idiopathic hypersomnia, and significant weight gain. Management requires ensuring adequate compliance, defined as utilizing the device for at least 5 nights per week and 4 hours per night, while optimizing patient adherence through heated humidifiers and ramp functions. For adherent patients experiencing persistent daytime sleepiness, wake-promoting stimulants such as modafinil and armodafinil, which increase extracellular dopamine levels, serve as highly effective and reliable therapeutic options to restore daytime alertness.
Referanslar
Otuyama LJ, Rizzi CF, Piovezan RD ve ark. The cholinergic system may play a role in the pathophysiology of residual excessive sleepiness in patients with obstructive sleep apnea. Medical Hypotheses 2013; 81: 509–11.
Pepin JL, Viot-Blanc V, Escourrou P, Racineuxe JL, Sapene M, Levy P. Prevalence of residual excessive sleepiness in CPAP-treated sleep apnoea patients: the French multicentre study. Eur Respir J 2009; 33: 1062–1067.
Karadağ M. Moderatör. CPAP Tedavisine Persistan Uykululuk, Değerlendirme ve Tedavi. Santamaria J, Iranzo A, Montserrat JM, Pablo J. Persistent sleepiness in CPAP treated obstructive sleep apnea patients: Evaluation and treatment. Sleep Medicine Reviews 2007: 195-207. http:// gogus-hast-tuberkuloz.uludag.edu.tr/literatur6.pdf
Boethel CD, Al-Sadi A, Barker JA. Residual Sleepiness in Obstructive Sleep Apnea Differential Diagnosis, Evaluation, and Possible Causes. Sleep Med Clin 2013; 8: 571–82.
Pack AI. Advances in sleep-disordered breathing. Am J Respir Crit Care Med 2006; 173: 7-15.
Obstructive Sleep Apnoea Syndrome. Report of Joint Nordic Project. Finnish Office for Health Care Technology Assessment. (FinOHTA), Helsinki. 2007; 172-4.
NSF (National Sleep Foundation) 2000 Omnibus Sleep in America Poll, 2000. http://www. sleepfoundation. org/publications/2001poll.html
Kjelsberg FN, Ruud EA, Stavem K. Predictors of symptoms of anxiety and depression in obstructive sleep apnea. Sleep Med 2005; 6: 341–6.
Nishino S, Mignot E. Wake-Promoting Medications: Basic Mechanisms and Pharmacology. In: Kryger MH, Roth T, Dement W (eds). Principles and Practice of Sleep Medicine; Expert Consult Premium Edition. 2010; 520-2.
Dixon JB, Schachter LM, O’Brien PE. Polysomnography before and fter weight loss in obesepatients with severe sleep apnea. In J Obes 2005; 29: 1048-54.
Berry RB, Budhiraja R, Gottlieb DJ, et al. Rules for Scoring Respiratory Events in Sleep: Update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. DoIiborations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. Darien, IL.: American Academy of Sleep Medicine, 2012; 8: 597-619
Nishino S, Mao J, Sampathkumaran R, Shelton J. Increased dopami¬nergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online 1998; 1: 49-61.
Mignot E, Nishino S, Guilleminault C, Dement WC. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994; 17: 436-7.
Pack AI, Black JE, Schwartz JR, et al. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med 2001; 164:1675–81.
Schwartz JR, Hirshkowitz M, Erman MK, et al. Modafinil as adjunct therapy for daytime sleepiness in Residual Sleepiness in OSA 581 obstructive sleep apnea: a 12-week, open-label study. Chest 2003; 124: 2192–9.
